Bb Biotech AG BB BIOTECH ORD SHS
Bb Biotech AG BB BIOTECH ORD SHS/ CH0038389992 /
0JYO
16/08/2024 16:40:02
|
Diferencia
+0.50
|
Volumen |
Bid17:40:06 |
Ask17:40:06 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
40.40CHF
|
+1.25%
|
2,984 Volumen de negocios: 120,747.25 |
-Volumen de oferta: - |
-Tamaño/ Volumen/ Formato de Ask: - |
2.22 mil millonesCHF |
4.98% |
- |
Descripción de negocio
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world’s largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech’s investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
Consejo de gestión & Consejo de supervisión
CEO |
Dr. Daniel Koller |
Consejo de gestión |
Dr. Thomas von Planta, Laura Hamill, Dr. Pearl Huang, Prof. Dr. Mads Krogsgaard Thomsen, Camilla Soenderby |
Consejo de supervisión |
Dr. Clive Meanwell |
Datos de la empresa
Nombre: |
BB Biotech AG |
Dirección: |
Schwertstraße 6,CH-8200 Schaffhausen/Schweiz |
Teléfono: |
+41-52-624-0845 |
Fax: |
- |
E-mail: |
info@bbbiotech.com
|
Internet: |
www.bbbiotech.com |
Industria: |
Financial |
Sector: |
Specialty Finance |
Subsector: |
Diversified Financial |
Fin del año financiero: |
31/12 |
Acciones de libre circulación: |
97.00% |
Fecha de OPI: |
10/12/1997 |
Relación con inversores
Nombre: |
Dr. Silvia Siegfried-Schanz |
IR teléfono: |
+41-44-267-7266 |
IR-fax: |
- |
IR e-mail: |
ssc@bellevue.ch
|
Accionistas mayoritarios
Freefloat |
|
96.47% |
Lazard Asset Management LLC, New York, USA |
|
3.53% |